MedPath

Zhejiang Jingxin Pharmachutical Co.,ltd.

Zhejiang Jingxin Pharmachutical Co.,ltd. logo
🇨🇳China
Ownership
Public
Established
1999-02-13
Employees
1.6K
Market Cap
-
Website
https://www.jingxinpharm.com
Introduction

The company was founded in 1990 and is a listed pharmaceutical company integrating R&D, production and sales. The company follows the business policy of “strengthening the main pharmaceutical industry and developing medical devices”, adheres to the core corporate values of “pragmatism, innovation, inclusiveness and win-win”, takes “careful protection of health” as its mission, and is committed to becoming a leader in the mental, neurological, cardiovascular and cerebrovascular fields in China. The company is mainly engaged in R&D, production and sales of chemical preparations, traditional Chinese medicines, biological agents, chemical raw materials, and medical devices. The company's main products are rehabilitation solutions, Bacillus lichens active bacteria capsules, simvastatin tablets, robustatin calcium tablets, pivastatin calcium dispersible tablets, sertraline hydrochloride tablets, levetiracetam tablets, praxol tablets, carbalatin bitartrate capsules, didacinib capsules and other preparations, as well as quinolones, statins, neuropsychiatric raw materials and medical display products. The company has been on the “China Chemical and Pharmaceutical Industry Excellent Pharmaceutical Export Enterprise Brand”, “China's Top 100 Pharmaceutical Industry” and “China's Top 100 Chemical and Pharmaceutical Companies List” for many years. Patented technology related to product processes has won the Chinese Patent Gold Award, the first prize of the Zhejiang Intellectual Property Award, and the first prize of the Zhejiang Science and Technology Progress Award.

Schizophrenia Market Set for Strong Growth, Driven by Novel Therapies

• The schizophrenia market is expected to grow significantly, driven by the launch of novel therapies and increased diagnosis rates. • Long-acting injectables (LAIs) are gaining traction despite higher costs, offering an alternative to oral antipsychotics. • The US dominates the schizophrenia market due to a large patient population and high drug costs. • Emerging treatments like Cobenfy, evenamide, Ingrezza, and iclepertin aim to address unmet needs in managing both positive and negative symptoms.
© Copyright 2025. All Rights Reserved by MedPath